<bill session="116" type="h" number="4619" updated="2022-11-01T13:49:42Z">
  <state datetime="2019-10-08">REFERRED</state>
  <status>
    <introduced datetime="2019-10-08"/>
  </status>
  <introduced datetime="2019-10-08"/>
  <titles>
    <title type="display">Pharmaceutical REPAI Act</title>
    <title type="official" as="introduced">To amend title XVIII of the Social Security Act to require drug manufacturers to pay a Medicare part D rebate for certain drugs if the price of such drugs increases faster than inflation.</title>
    <title type="short" as="introduced">Pharmaceutical Rebates for Excessive Pricing Above Inflation Act</title>
    <title type="short" as="introduced">Pharmaceutical REPAI Act</title>
  </titles>
  <sponsor bioguide_id="S001145"/>
  <cosponsors>
    <cosponsor bioguide_id="H001038" joined="2019-10-08"/>
    <cosponsor bioguide_id="W000826" joined="2019-10-08"/>
  </cosponsors>
  <actions>
    <action datetime="2019-10-08">
      <text>Introduced in House</text>
    </action>
    <action datetime="2019-10-08" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2019-10-08">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2019-10-08">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
    <action datetime="2019-10-09">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
    <committee code="HSWM" name="House Ways and Means" subcommittee="" activity="Referral"/>
    <committee code="HSWM02" name="House Ways and Means" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="h" number="3" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Business records"/>
    <term name="Civil actions and liability"/>
    <term name="Government information and archives"/>
    <term name="Government trust funds"/>
    <term name="Health care costs and insurance"/>
    <term name="Inflation and prices"/>
    <term name="Medicare"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2020-11-03T21:41:58Z" status="Introduced in House">Pharmaceutical Rebates for Excessive Pricing Above Inflation Act or the Pharmaceutical REPAI Act

This bill requires drug manufacturers, subject to civil penalties, to issue rebates to the Centers for Medicare &amp; Medicaid Services for covered drugs under the Medicare prescription drug benefit that cost $100 or more and for which the average manufacturer price increases faster than inflation.</summary>
</bill>
